Latest Asx Continuous Disclosure News

Sequoia Financial Group has acknowledged that ASIC’s civil penalty proceedings against its subsidiary InterPrac are material and confirmed timely disclosure to the market following formal notification.

Cauldron Energy Limited addresses a sharp share price rise, attributing it to strong uranium exploration results and market speculation linked to a sector takeover.

Lodestar Minerals has responded to ASX queries clarifying the timing and disclosure of key assay results from its Ned’s Creek gold project and detailed the procedural steps behind its Arizona Mountain Pass rare earths acquisition.

DroneShield Limited has clarified the recent exercise and sale of shares by its directors following performance option vesting, alongside addressing an erroneous contract announcement that was later withdrawn. The company also outlined steps to enhance compliance with ASX continuous disclosure and trading policies.

Zoono Group Limited has clarified the recent spike in its share price and trading volume, linking it to a new South African packaging agreement and a freshly announced contract with Multisteps Pty Ltd.

DroneShield Limited has clarified the recent sharp decline in its share price, attributing the market movement to disclosed director share disposals rather than any undisclosed material information.

Resolution Minerals has clarified its compliance with ASX disclosure rules following a $2 million placement to Tribeca Investment Partners, confirming the transaction's material impact on its share price.

Vectus Biosystems has responded to an ASX price query following a dramatic spike in its share price and trading volume, denying any undisclosed information and confirming compliance with ASX rules.

Gladiator Resources has provided detailed clarifications to the ASX regarding its agreement with Apex USA Resources LLC for rare earth tenements in California, highlighting ongoing disputes and incomplete project milestones.

Chimeric Therapeutics has responded to ASX inquiries regarding the disclosure timing and materiality of new clinical data from its ADVENT-AML trial, emphasizing compliance with continuous disclosure rules and the careful verification of promising patient responses.

Bentley Capital Limited has addressed a sharp 70% rise in its share price and a spike in trading volume, attributing the movement to ongoing legal proceedings rather than undisclosed information.

4DS Memory Limited reveals a pivotal quarter marked by a strategic review, executive departures, and a contentious board nomination ahead of its AGM.